Published in Vaccine Weekly, April 1st, 1996
Hepatitis B (HBV), a disease prevalent in approximately 350 million people worldwide, causes two million deaths annually. The only approved treatment in the U.S. is alpha interferon, which cures only a small percentage of patients and is often accompanied by undesirable side effects. Poor tolerance due to side effects associated with alpha interferon is believed to derive from stimulation of a general immune response that is not disease-specific.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly